TY - JOUR
T1 - Measures to prevent and treat Nipah virus disease
T2 - research priorities for 2024–29
AU - Moore, Kristine A.
AU - Mehr, Angela J.
AU - Ostrowsky, Julia T.
AU - Ulrich, Angela K.
AU - Moua, Nicolina M.
AU - Fay, Petra C.
AU - Hart, Peter J.
AU - Golding, Josephine P.
AU - Benassi, Virginia
AU - Preziosi, Marie Pierre
AU - Broder, Christopher C.
AU - de Wit, Emmie
AU - Formenty, Pierre B.H.
AU - Freiberg, Alexander N.
AU - Gurley, Emily S.
AU - Halpin, Kim
AU - Luby, Stephen P.
AU - Mazzola, Laura T.
AU - Montgomery, Joel M.
AU - Spiropoulou, Christina F.
AU - Mourya, Devendra T.
AU - Parveen, Shahana
AU - Rahman, Mahmudur
AU - Roth, Cathy
AU - Wang, Lin Fa
AU - Osterholm, Michael T.
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024
Y1 - 2024
N2 - Nipah virus causes highly lethal disease, with case-fatality rates ranging from 40% to 100% in recognised outbreaks. No treatments or licensed vaccines are currently available for the prevention and control of Nipah virus infection. In 2019, WHO published an advanced draft of a research and development roadmap for accelerating development of medical countermeasures, including diagnostics, therapeutics, and vaccines, to enable effective and timely emergency response to Nipah virus outbreaks. This Personal View provides an update to the WHO roadmap by defining current research priorities for development of Nipah virus medical countermeasures, based primarily on literature published in the last 5 years and consensus opinion of 15 subject matter experts with broad experience in development of medical countermeasures for Nipah virus or experience in the epidemiology, ecology, or public health control of outbreaks of Nipah virus. The research priorities are organised into four main sections: cross-cutting issues (for those that apply to more than one category of medical countermeasures), diagnostics, therapeutics, and vaccines. The strategic goals and milestones identified in each section focus on key achievements that are needed over the next 6 years to ensure that the necessary tools are available for rapid response to future outbreaks of Nipah virus or related henipaviruses.
AB - Nipah virus causes highly lethal disease, with case-fatality rates ranging from 40% to 100% in recognised outbreaks. No treatments or licensed vaccines are currently available for the prevention and control of Nipah virus infection. In 2019, WHO published an advanced draft of a research and development roadmap for accelerating development of medical countermeasures, including diagnostics, therapeutics, and vaccines, to enable effective and timely emergency response to Nipah virus outbreaks. This Personal View provides an update to the WHO roadmap by defining current research priorities for development of Nipah virus medical countermeasures, based primarily on literature published in the last 5 years and consensus opinion of 15 subject matter experts with broad experience in development of medical countermeasures for Nipah virus or experience in the epidemiology, ecology, or public health control of outbreaks of Nipah virus. The research priorities are organised into four main sections: cross-cutting issues (for those that apply to more than one category of medical countermeasures), diagnostics, therapeutics, and vaccines. The strategic goals and milestones identified in each section focus on key achievements that are needed over the next 6 years to ensure that the necessary tools are available for rapid response to future outbreaks of Nipah virus or related henipaviruses.
UR - http://www.scopus.com/inward/record.url?scp=85198523575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85198523575&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(24)00262-7
DO - 10.1016/S1473-3099(24)00262-7
M3 - Review article
C2 - 38964362
AN - SCOPUS:85198523575
SN - 1473-3099
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
ER -